Chelsea Therapeutics International reports positive study resultsChelsea Therapeutics International, Ltd. (Nasdaq: CHTP) reported positive results from its human bioequivalence study of its lead product candidate in the pharmaceutical company to be used in a Phase II evaluation in the treatment of rheumatoid arthritis. Specifically, the company quantified the improvements in relative bioavailability demonstrated by disodium salt formulation of CH-1504 and identified doses to be used in a Phase II evaluation in the treatment of rheumatoid arthritis Shares of Chelsea jumped 12.93%, or $0.79 to $6.90 in pre-market trading. spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer
|
Research
|
